Navigation Links
Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer

HUNTSVILLE, Ala., April 16, 2007 /PRNewswire/ -- Expression Genetics, Inc., announced today the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001. The study, conducted at The University of Alabama at Birmingham and , evaluated the safety, tolerance, preliminary efficacy, and biological activity of the EGEN-001 in 13 patients with advanced recurrent epithelial ovarian cancer. The product, utilizing the Company's proprietary TheraPlas(R) delivery technology, is composed of interleukin-12 (IL-12) gene expression plasmid formulated with a biocompatible delivery polymer and is designed to increase local concentration of IL-12 protein. IL-12 is a potent anti-cancer cytokine which works by enhancing the body's immune system against cancer and inhibiting tumor blood supply. EGEN-001 for treatment of ovarian cancer has been granted Orphan Drug Status by the FDA.

The Phase I clinical trial was an open-label dose escalation study involving four dose levels of EGEN-001 administered intraperitoneally by four weekly infusions in chemotherapy-resistant advanced stage recurrent ovarian cancer patients. The treatment was well tolerated with no apparent dose- related trends in clinical laboratory, ECG, or vital sign parameters. General observations included abdominal cramping, mild to moderate peritonitis, nausea, and mild elevation of body temperature. These data demonstrate that this IL-12 gene therapeutic is safe for intraperitoneal administration in ovarian cancer patients.

Several clinical and biological parameters were evaluated as secondary endpoints of this study. Tumor burden of patients was monitored during treatment and results show 31% of patients showed stable disease. To date, the overall median survival is over 12.2 months with 7 out of 13 patients still surviving. There appeared to be some trend with respect to clinical benefit in the patients treated with
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
2. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:5/21/2015)... 21, 2015  (MUSE Booth # 1510)What:Automating continuous ... (EHR) is invaluable in any hospital setting, but ... a requirement and mainstream in healthcare, the integration ... EHR is gaining traction in MEDITECH facilities.During MUSE ... Site Project Manager & Clinical Analyst at McLaren ...
(Date:5/21/2015)... Mai 2015 Dipexium Pharmaceuticals, ... Unternehmen für Arzneimittel im fortgeschrittenen Entwicklungsstadium, ... Vermarktung von Locilex® (Pexiganan-Creme 0,8 %) und ... wissenschaftliche Posterpräsentation an, welche das innovative ... OneStep-1 und OneStep-2, in der Locilex® ...
(Date:5/21/2015)... CHICAGO , May 21, 2015  Heidrick & ... executive search , leadership consulting and ... life sciences expertise among global practices announcing the addition ... Chicago office. Dietlin ... has worked globally and across R&D, Medical and Commercial ...
Breaking Medicine Technology:Hospital Streamlines ICU Efficiency with Timely Data Integration 2Hospital Streamlines ICU Efficiency with Timely Data Integration 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7Heidrick Increases Healthcare and Life Sciences Expertise 2
... at AACR, SAN DIEGO, April 17 /PRNewswire-FirstCall/ ... in vitro study showing,that the active metabolite ... response by inducing cytokine secretion,cytolysis of tumor ... a poster presentation at the Annual,Meeting of ...
... ANGELES, April 17, 2007 /PRNewswire/ -- Researchers from ... presented,strong evidence today that an antibiotic typically prescribed ... types of cancers. , Q. Ping Dou, Ph.D., ... lab announced the findings of their study showing,that ...
Cached Medicine Technology:Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 2Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 3Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 4Alzheimer's Drug Shows Promise in Fighting Cancer 2
(Date:5/24/2015)... 24, 2015 EnviroLeather™ by LDI, ... Plus” – a classic, rugged leather grain with ... difficult stains, including ink, to be easily removed. ... suitable for corporate, healthcare, hospitality and education environments. ... EnviroLeather’s goal of developing products that are more ...
(Date:5/24/2015)... 2015 Medicx Media Solutions ... executive Jay Krihak as its head of programmatic ... up its expertise and leadership position in the ... Health sectors. , Krihak is an experienced, award-winning ... Krihak led sales planning teams for mobile platform ...
(Date:5/23/2015)... 23, 2015 On May 13, Nithyananda ... a youngster's yogic power learned through meditation and initiation ... in Bangalore, India. , Yogamaatha, a nine-year-old girl from ... high profile professionals attending the 2015 Business Advocacy Summit ... -- blindfolded. , In a demonstration that lasted ...
(Date:5/23/2015)... Parker, CO (PRWEB) May 23, 2015 On ... participated in MuckFest. The event was a 5k mud obstacle ... affects more than 2 million people worldwide, and the reason ... our community,” said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. ... National Multiple Sclerosis Society.” , The event was not only ...
(Date:5/23/2015)... Add High-Quality prismatic refractions into footage using ... It's as simple as dragging and dropping footage into the ... full effect. , Including over 80 stunning flares, ProFlare ... making this the ultimate bundle for adding prismatic refractions to ... package are movie files designed for Final Cut Pro X, ...
Breaking Medicine News(10 mins):Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2
... high for some women, study suggests , , , TUESDAY, ... many women, mammography is far from perfect. But, undergoing ... more cancers in high-risk women, particularly those with dense ... study authors noted, ultrasound also significantly increases the rate ...
... Mich., May 13 CJPS Enterprises, LLC, (http://www.CJPS-Enterprises.com ... a,half-day mini-seminar and interactive discussions about building up, ... their,competitiveness, and therefore their worth. This seminar will ... 2008 and is applicable to both large,and small ...
... Attorneys for a married,couple who lived in the fundamentalist ... District Court judge today for an emergency order,to prevent ... is still,nursing, when he turns a year old on ... presiding judge at 3:30 p.m.,seeking an emergency injunction to ...
... SEATTLE, May 13 The Epilepsy Foundation,Northwest announces ... and Portland. The events will occur on Saturday, June ... Riverfront Park. The following,day, Sunday, June 22, Portland will ... from 9:30 am-12:00 pm., "Everyone is invited to ...
... Support Local 332 Nurses Negotiating With Genesys Regional,Medical Center, ... Hoffa and Michigan Lt. Gov. John Cherry will lead ... for more than 1,000,Local 332 nurses in contract negotiations ... to maintain low nurse-to-patient ratios and to,continue quality, affordable ...
... Pa., May 13 Vibra Healthcare, LLC,announced today ... Care Hospital,(LTACH) in southeastern Michigan. The 83 bed ... LTACH in Michigan. It will be known as,Vibra ... and rehabilitative care to medically,complex patients. These patients ...
Cached Medicine News:Health News:Coupled With Mammography, Ultrasound Finds More Breast Cancers 2Health News:Coupled With Mammography, Ultrasound Finds More Breast Cancers 3Health News:Intellectual Property Buildup Seminar to be Held in Detroit 2Health News:FLDS Couple Seeks Emergency Order to Stop Infant Seizure, Say Perry & Haas 2Health News:FLDS Couple Seeks Emergency Order to Stop Infant Seizure, Say Perry & Haas 3Health News:Vibra Healthcare Acquires the Kindred Long Term Acute Care Hospital in Southeastern Michigan 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: